secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001213900-24-078736
Event type: leadership
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna appoints Warner Biddle CEO, Christi Shaw to board; Maag resigns
-----------------------------------------------------------------------

- Warner Biddle appointed CEO and Class III director, effective Sept 16; previously SVP Global Head of Commercial at Kite Pharma.
- Biddle receives 2,579,259-share option (4-year vest, 1-yr cliff), $625K salary, $650K sign-on bonus, and up to $150K relocation.
- Peter Maag, Ph.D. resigned as CEO and director Sept 13; will provide contractor services for up to 6 mo at $45,833/mo plus $550K severance.
- Christi Shaw appointed Class II director; granted option for $350K in shares vesting over 36 months; succeeded Brian Kotzin, who resigned.
- Company adopted 2024 Inducement Equity Incentive Plan reserving 4M shares for new-hire equity grants, used for Biddle's option.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000121390024078736/0001213900-24-078736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000121390024078736/ea0214607-8k_kyverna.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-078736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer